• Nurix Therapeutics, Inc. reported first-quarter 2026 results with revenue of US$6.25 million versus US$18.45 million a year earlier, alongside a wider net loss of US$87.17 million and a basic loss per share of US$0.79 from continuing operations.
• At the same time, Nurix highlighted progress in its targeted protein degradation pipeline, including patient enrollment in the Phase 2 DAYBreak CLL-201 trial for bexobrutideg and plans for a global Phase 3 confirmatory study to support potential accelerated and full approvals.
• We will now examine how Nurix’s weaker quarterly revenue alongside its advancing bexobrutideg Phase 2 program shapes the company’s investment narrative.

AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

What Is Nurix Therapeutics' Investment Narrative?

To own Nurix, you really have to buy into the idea that its targeted protein degradation platform, and especially bexobrutideg, can eventually justify years of heavy investment despite persistent losses. The latest quarter underlines that tension: revenue fell to US$6.25 million while the net loss widened to US$87.17 million, yet Nurix is pushing ahead with the Phase 2 DAYBreak CLL-201 trial and preparing a global Phase 3 program. That mix keeps the near term story firmly centered on clinical catalysts rather than financial momentum, and the market’s relatively muted share price reaction suggests these numbers did not fundamentally reset expectations. The more immediate question is whether Nurix can sustain this level of cash burn long enough to see bexobrutideg and the broader pipeline through key readouts.

However, one risk around funding and dilution may matter more than it first appears. According our valuation report, there's an indication that Nurix Therapeutics' share price might be on the expensive side.

Exploring Other Perspectives

The single Simply Wall St Community fair value estimate clusters at about US$30 per share, but recent results highlight widening losses and execution risk that could strongly influence how different investors reassess Nurix’s prospects.

Explore another fair value estimate on Nurix Therapeutics - why the stock might be worth as much as 86% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Nurix Therapeutics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Nurix Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nurix Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Find 62 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.